VVector Bio

Want to learn more about the Critical Quality Attributes of AAV? Check out this great resource!

Valuable insights to consider when choosing a CDMO!

Empty AAV capsids are a big problem. Therapy efficacy and safety is hindered by them. But this study outlines a method to help fix this issue. Empty capsids are an unfortunate byproduct of AAV production.  They can: - Reduce transduction efficacy - Cause particle aggregation - Trigger adverse immune responses in patients The authors outline a combination of three methods to remove these capsids in downstream: 𝟭. 𝗔𝗻𝗶𝗼𝗻 𝗘𝘅𝗰𝗵𝗮𝗻𝗴𝗲 𝗖𝗵𝗿𝗼𝗺𝗮𝘁𝗼𝗴𝗿𝗮𝗽𝗵𝘆 (𝗔𝗘𝗫):  - Developed to separate full from empty capsids, utilizing dual salt gradients for optimal resolution 𝟮. 𝗗𝘂𝗮𝗹 𝗦𝗮𝗹𝘁 𝗟𝗶𝗻𝗲𝗮𝗿 𝗚𝗿𝗮𝗱𝗶𝗲𝗻𝘁:  - The combination of MgSO₄ and MgCl₂ was employed to achieve superior capsid separation compared to single salt gradients 3. 𝗛𝗼𝗹𝗱𝗶𝗻𝗴 𝗦𝘁𝗲𝗽 𝗣𝗼𝘀𝘁-𝗘𝗺𝗽𝘁𝘆 𝗣𝗲𝗮𝗸:  - Implemented to optimize the resolution between full and empty capsid peaks Main Findings: - The optimized method achieved up to a 5-fold enrichment of full capsids, with final product purity reaching 77% full capsids - The dual salt gradient (MgSO₄ mixed with MgCl₂) provided better separation of full and empty capsids than single salt methods - Adding a low concentration of MgSO₄ to the load buffer reduced what is believed to be AAV degradation on the chromatography column Many thanks to the authors who put this together! Ashton Lavoie, Michael Guerrero and colleagues What are your thoughts on this method? Share them below!

🌍 Revolutionizing Viral Vector Manufacturing Through Global Collaboration! 🌍 (Français ci-dessous) At VVector Bio, we're thrilled to announce our participation in a pioneering project aimed at transforming the landscape of viral vector manufacturing. Backed by a £1.1 million grant from Innovate UK and the National Research Council of Canada, we are joining forces with National Research Council Canada / Conseil national de recherches Canada, Revvity and Abselion to address the critical challenges in cell and gene therapy production. Current viral vector production faces significant hurdles, including low yields, scalability issues, and high costs. Together, we’re tackling these challenges head-on by integrating genomics, epigenomics, and innovative process monitoring to optimize and enhance the HEK-293 cell platform. This collaboration not only underscores our commitment to advancing biomanufacturing but also highlights the importance of international partnerships in driving innovation. We're excited to see the breakthroughs this project will bring, ensuring that life-changing therapies reach patients faster and more efficiently. Read the full press release here: https://lnkd.in/eDk_XE4n #ViralVectors #GeneTherapy #Biomanufacturing #Innovation #VVectorBio #NRC #Revvity #Abselion --- 🌍 Révolutionner la Fabrication de Vecteurs Viraux Grâce à une Collaboration Internationale ! 🌍 Chez VVector Bio, nous sommes ravis d’annoncer notre participation à un projet novateur visant à transformer la fabrication de vecteurs viraux. Soutenus par une subvention de £1,1 million d'Innovate UK et du Conseil national de recherches du Canada, nous unissons nos forces avec le National Research Council Canada / Conseil national de recherches Canada, Revvity, et Abselion pour relever les défis cruciaux de la production de thérapies cellulaires et géniques. La production actuelle de vecteurs viraux est confrontée à des obstacles importants, notamment des rendements faibles, des problèmes d'évolutivité et des coûts élevés. Ensemble, nous relevons ces défis en intégrant des innovations de pointe en génomique, épigénomique et surveillance des processus pour optimiser et améliorer la plateforme cellulaire HEK-293. Cette collaboration souligne non seulement notre engagement à faire progresser les thérapies cellulaires et géniques, mais aussi l'importance des partenariats internationaux pour stimuler l'innovation. Nous sommes impatients de voir les percées que ce projet apportera, garantissant que des thérapies révolutionnaires parviennent plus rapidement et plus efficacement aux patients. Lisez le communiqué de presse complet ici : https://lnkd.in/eDk_XE4n #VecteursViraux #ThérapieGénique #Bioproduction #Innovation #VVectorBio #CNRC #Revvity #Abselion

We are participating in the "ADVANCING MANUFACTURE OF CELL AND GENE THERAPIES VIII" conference in San Diego from Feb 4-8th. Our CEO Alina Venereo-Sanchez is chairing one of the sessions and also presenting our most recent development- A single plasmid technology for AAV production in HEK-293 cells. This technology not only reduce manufacturing cost by reducing the amount of plasmids for transfection but also double AAV yields. Don't hesitate to come talk to us if you are at the conference! #atmps #cellandgenetherapies #manufacturing #cgt

Super exciting to be participating at the Advanced Therapies Week in Miami! First time VVector Bio has his own booth at the Innovation Zone-Pod 19. If you are attending don't hesitate to come talk to us!